115
15. 3. 2006.
Extended follow‐up of a phase II trial in relapsed, refractory multiple myeloma:
Bortezomib, a first‐in‐class proteasome inhibitor, has shown clinical activity in relapsed, refractory multiple myeloma in a pivotal Phase II trial, SUMMIT.